Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Karlsson K, Strömberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A, Kimby E, Lärfars G, Cristiansen I, Nilsson G, Celsing F, Sundström G, Luthman M, Tidefelt U, Wallvik J, Juliusson G. Karlsson K, et al. Among authors: celsing f. Br J Haematol. 2002 Mar;116(3):538-48. doi: 10.1046/j.0007-1048.2001.03296.x. Br J Haematol. 2002. PMID: 11849209 Free article. Clinical Trial.
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. Lundin J, et al. Among authors: celsing f. Blood. 2002 Aug 1;100(3):768-73. doi: 10.1182/blood-2002-01-0159. Blood. 2002. PMID: 12130484 Free article. Clinical Trial.
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Lundin J, Osterborg A, Björkholm M, Björkstrand B, Celsing F, Hjalmar V, Linder O, Luthman M, Merup M, Tidefelt U, Mellstedt H; Myeloma Group of Central Sweden. Lundin J, et al. Among authors: celsing f. Hematol J. 2003;4(4):248-52. doi: 10.1038/sj.thj.6200301. Hematol J. 2003. PMID: 12872149 Clinical Trial.
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P. Hast R, et al. Among authors: celsing f. Leukemia. 2003 Sep;17(9):1827-33. doi: 10.1038/sj.leu.2403035. Leukemia. 2003. PMID: 12970783 Clinical Trial.
Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K, Mellqvist UH, Wallhult E, Carneskog J, Kimby E, Celsing F, Brune M. Hellstrand K, et al. Among authors: celsing f. Leuk Lymphoma. 1997 Nov;27(5-6):429-38. doi: 10.3109/10428199709058309. Leuk Lymphoma. 1997. PMID: 9477124
48 results